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Summary 
 
Wnt factors regulate tissue formation during development and tissue homeostasis in adult 
life. Upon binding to plasma membrane receptors, Wnt factors trigger Wnt/-catenin 
(canonical) signaling pathway or several other -catenin-independent (non-canonical) 
pathways. Activation of Wnt/-catenin signaling leads to nuclear accumulation of -catenin 
which acts as a transcriptional coactivator of T-cell factor/Lymphoid enhancer factor 
(TCF/LEF) target genes involved in numerous cellular processes. Aberrant activation of 
Wnt/-catenin signaling occurs in several human cancers and other diseases. The most active 
vitamin D3 metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and its receptor (VDR) 
regulate Wnt/-catenin signaling in a tissue-specific manner. 1,25(OH)2D3/VDR inhibits -
catenin/TCF transcriptional activity in colon cancer cells, while upregulation of the Wnt/-
catenin pathway by either ligand-activated or unliganded VDR promotes bone formation or 
hair follicle differentiation, respectively. This crosstalk with Wnt/-catenin signaling may 
contribute to the protective action of 1,25(OH)2D3 against colon cancer and to its effects on 
tissue homeostasis. 
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I. INTRODUCTION 
The most active vitamin D3 metabolite 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3, calcitriol), 
is a pleiotropic hormone with cell type-dependent effects on cell proliferation, survival, 
differentiation and function. 1,25(OH)2D3 exerts its actions via binding and modulation of the 
vitamin D receptor (VDR), a member of the nuclear receptor superfamily of transcriptional 
regulators. 1,25(OH)2D3 triggers a complex network of gene regulatory (genomic) effects. It 
also modulates in a transcription-independent manner the activity of several types of 
signaling enzymes and ion channels (non-genomic effects). In addition, 1,25(OH)2D3/VDR 
regulates cell phenotype and function through crosstalk with other signal transduction 
pathways. Research in the last decade has revealed that an important mechanism of 
1,25(OH)2D3/VDR action in certain tissues is related to its interaction with the Wnt/β-catenin 
pathway. In this chapter, we will review the evidence and comment on the significance of 
this interplay, which highlights the biological relevance of 1,25(OH)2D3 and opens new 
possibilities for the therapeutic use of vitamin D and its analogues. 
 
II. WNT SIGNALING 
Wnt factors are a family of highly conserved secreted glycoproteins that regulate cell 
proliferation, differentiation, polarity, movement, and survival during development and in 
adult tissue homeostasis [1-3]. The 19 human Wnts are cystein-rich molecules with 350-400 
aminoacids and highly related structures [4]. In addition to bearing an N-terminal signal 
peptide, Wnts undergo N-glycosylation which is required for secretion. They are also 
modified by the addition of two lipids, palmitic and palmitoleic acids, which may accounts 
for the hydrophobicity and poor solubility of Wnt proteins, and thus explain their low range 
distribution and predominantly autocrine-paracrine activity [5, 6]. Lipid modification is also 
required for the signaling activity of the secreted protein [7]. 
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Several membrane receptors and coreceptors for Wnt proteins have been described: 
Frizzled family members (10 in humans), low-density lipoprotein receptor-related proteins 
(LRP) 5 and 6 (Arrow, in Drosophila), and RYK (Derailed, in Drosophila) and ROR2 
families of single-pass transmembrane receptor tyrosine kinases. Upon binding to their 
receptors, Wnts trigger different signaling pathways: the so-called canonical or Wnt/β-
catenin pathway and the β-catenin-independent, non-canonical pathways [3]. 
 
A. The Wnt/-Catenin Pathway 
In normal epithelial cells, β-catenin protein is bound to the intracellular domain of the 
transmembrane E-cadherin protein in the intercellular adhesion structures adherens junctions. 
-Catenin links E-cadherin to the actin cytoskeleton through its simultaneous binding to α-
catenin, which is directly and indirectly bound to actin filaments. In the absence of Wnt 
factors β-catenin is mostly found at adherens junctions (Figure 1A). Free -catenin is 
phosphorylated by casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3) in a so-
called destruction complex that also contains the scaffolding proteins Axin and APC. 
Phosphorylated -catenin is ubiquitinated by the E3 ubiquitin ligase β-transducin repeat-
containing protein (-TrCP), and thus targeted for degradation by the proteasome [3] (Figure 
1A). Wnt binding to Frizzled and the subsequent formation of a ternary complex with 
LRP5/6 coreceptor induces -catenin protein stabilization (Figure 1B). Wnt binding to 
Frizzled/LRP triggers co-clustering of receptor complexes in signaling structures named 
LRP-signalosomes, which leads to phosphorylation of LRP by GSK3β and CK1γ located in 
the vicinity of the plasma membrane [8, 9]. Axin docking to the phosphorylated residues in 
LRP promotes the inactivation of the destruction complex and the accumulation of β-catenin 
(Figure 1B). Then, a population of -catenin molecules translocate into the cell nucleus, 
where they join members of the T-cell factor/Lymphoid enhancer factor (TCF/LEF: TCF1, 
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TCF2/LEF1, TCF3 and TCF4) family of transcription factors (Figure 1B). TCF/LEFs bind to 
specific DNA sequences referred to as Wnt responsive elements (WRE: CCTTTGA/TA/T). 
In the absence of Wnt signals, TCF/LEF proteins are mostly repressors although in some 
cases they may activate transcription of their target genes. TCF/LEFs repress gene expression 
by interacting with corepressors such as Groucho/TLE1, which promotes histone 
deacetylation and chromatin compaction (Figure 1A). Binding of β-catenin to TCF/LEFs 
displace corepressors [10] and recruits a plethora of coactivators which trigger transcriptional 
activation of TCF/LEF-bound genes that were previously repressed (Figure 1B). β-Catenin-
associated coactivators include BCL9 and Pygo, Mediator complex, p300/CBP and 
TRRAP/TIP60 histone acetyltransferases (HATs), MLL1/2 histone metyltransferases 
(HMTs), the SWI/SNF family of ATPases for chromatin remodelling, telomerase, and the 
PAF1 complex for transcription elongation and histone modification [11-13]. Intriguingly, 
recent evidence suggests that during Wnt-induced transcription β-catenin and its coactivators 
cycle on and off the WRE with a 60 min periodicity and are replaced by Groucho/TLE1 [3, 
14, 15]. Recently also, APC has been found to antagonize -catenin/TCF-dependent 
transcription by promoting the exchange of coactivators with corepressors within the nucleus 
in a stepwise and oscillating manner [14]. Thus, both coactivators and corepressors appear to 
be active during β-catenin-mediated transcription. 
PLEASE, INSERT FIGURE 1 HERE 
Numerous β-catenin/TCF or Wnt target genes have been identified in diverse 
biological systems and they are mostly cell- and context-specific [16]. Products of Wnt target 
genes have a large variety of biochemical functions including cell cycle kinase regulation, 
cell adhesion, hormone signaling, and transcription regulation. The plurality and diversity of 
these biochemical functions reflect the variety of different biological effects of the Wnt 
pathway, including activation of cell cycle progression and proliferation, inhibition of 
 6 
apoptosis, and regulation of embryonic development and cell differentiation, growth and 
migration [16]. For a comprehensive, updated overview of β-catenin/TCF target genes, we 
recommend Roel Nusse´s Wnt homepage 
(http://www.stanford.edu/~rnusse/wntwindow.html). 
Deregulation or abnormal activation in adult life of the Wnt/β-catenin signaling 
pathway contributes to the emergence and progression of several types of human cancer. This 
is not surprising as the Wnt1 gene (Int1 was its first name) was discovered in mouse 
mammary carcinomas as a target of insertional activation by the mouse mammary tumor 
virus [17]. Cancer cells with mutationally activated Wnt pathway overexpress at least 20 
target genes that activate proliferation including proto-oncogenes c-MYC, c-JUN, and 
CCND1/cyclin D1 [16]. 
 
B. Non-Canonical Wnt Pathways 
Non-canonical Wnt pathways are very diverse and are still evolving into an increasing 
number of branches [18]. Among them, Wnt/planar cell polarity (PCP) and Wnt/calcium 
pathways are relatively better characterized. 
The Wnt/PCP pathway was described in Drosophila melanogaster. It regulates the 
polarity of epithelial cells within the plane of the epithelium, e.g. orienting Drosophila wing 
hairs or regulating the organization of the ommatidia in the fly eye [19]. In vertebrates, a 
similar pathway has been described regulating convergent extension movements during 
gastrulation or neurulation and migration of neural crest cells [20-22]. The core element of 
the Wnt/PCP pathway includes the activation of Rho GTPases such as RhoA, Rac, or Cdc42 
that can activate more downstream mediators like Jun N-terminal kinase (JNK) or Rho 
kinase (ROCK). Our understanding of PCP signaling has increased dramatically in the past 
years and its role in diseases such as cancer is an area of intense research (reviewed in [23]). 
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 Some Wnts (e.g. Wnt5a or Wnt11) can induce a rapid release of intracellular calcium that 
depends on heterotrimeric G proteins [24] and the activation of the phosphatidylinositol cycle 
[25]. This increase in calcium concentration activates different intracellular calcium-sensitive 
enzymes such as protein kinase C [26, 27], calcium-calmodulin-dependent kinase II [28], and 
the phosphatase calcineurin, which subsequently activates the transcription factor NFAT [29, 
30]. This pathway is involved in dorsoventral patterning of early Xenopus laevis and 
zebrafish embryos [28, 29, 31], regulation of the Wnt/β-catenin pathway [32], tumor 
formation [33-35], and the regulation of epithelial-mesenchymal transitions [36] 
 
C. Wnt Inhibitors 
In line with its crucial roles in essential processes during development and adult life, Wnt 
action is antagonized or modulated by numerous molecules that act at different locations and 
by different mechanisms. Extracellular inhibitors are secreted molecules that either bind Wnt 
factors in solution, thus preventing their interaction with the plasma membrane receptors or 
inhibit Wnt signaling by binding to LRP5/6 (Figure 2). The first group comprises secreted 
Frizzled receptor-related proteins (SFRPs), Wnt inhibitory factor-1 (WIF-1), Crescent and 
Xenopus Cerberus [37]. Wnt inhibitors that bind LRP5/6 include the Dickkopf (Dkk) and 
WISE/SOST families [38-41] (Figure 2). In addition, an increasing number of intracellular 
inhibitors of Wnt signaling are known. Some of them function in the cytosol such as Naked 
or Axin2/Conductin [42-44], while others such as Chibby or ICAT block β-catenin action 
within the cell nucleus either by direct binding or by binding to -catenin partners and the 
promotion of β-catenin nuclear export [45, 46]. 
PLEASE, INSERT FIGURE 2 HERE 
The Dickkopf gene family encodes secreted proteins of 255-350 aminoacids and 
comprises four main members in vertebrates (Dkk-1 to -4) [41]. A distant Dkk family 
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member, Dkk-L/sgy (Dickkopf-like protein 1 or soggy), has been described in vertebrates [47] 
and shows unique homology to Dkk-3. Dkk-1 and Dkk-4 proteins act as pure inhibitors of 
Wnt/-catenin signaling. In contrast, Dkk-2 and Dkk-3 can activate or inhibit the pathway 
depending on the cellular context [41, 48, 49]. The inhibitory effect of Dkks may be induced 
by two mechanisms. First, Dkk binding to LRP5/6 can directly block the Wnt-Frizzled-LRP 
interaction [50]. And second, Dkks can form a ternary complex with LRP5/6 and another 
class of high affinity Dkk receptors named Kremen (Krm1/2), which induces rapid 
endocytosis and removal of LRP5/6 from the plasma membrane, thereby blocking Wnt/-
catenin signaling [51, 52]. Recent biochemical and genetic studies suggest that Dkk-1 
disruption of the Wnt-induced Frizzled-LRP6 complex is a more likely mechanism [53], with 
Kremen playing a minor modulatory role in specific tissues [54]. 
 
III. ANTAGONISM OF WNT/β-CATENIN PATHWAY BY 1,25(OH)2D3 IN COLON 
CANCER 
A. Wnt Signaling in Normal Colon and Colon Cancer 
Colon is lined with a specialized simple epithelium organized into crypts (deep 
invaginations) and a flat surface epithelium. The bottom half of the crypts host highly 
proliferative progenitor cells named transit-amplifying cells which give rise to two different 
cell lineages: the absorptive enterocytes and the secretory cells (mucus-secreting goblet cells 
and hormone-secreting enteroendocrine cells). Maturation of progenitor cells coincides with 
upward migration. Upon reaching the surface epithelium, the differentiated cells undergo 
apoptosis and are shed into the lumen. The self-renewing capacity of the colon depends on 
the presence of stem cells at the crypt bottom [55, 56]. 
The Wnt/-catenin pathway is the main driving force behind the proliferation of 
epithelial cells in the colonic crypts and functional studies have confirmed that this pathway 
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constitutes the master switch between proliferation and differentiation of the epithelial cells 
[57, 58]. Thus, active Wnt signaling is essential for the maintenance of crypt progenitor 
compartments in the intestine. This is evidenced by mice lacking the Tcf4 transcription factor 
[59], by the conditional depletion of -catenin from the intestinal epithelium [60, 61], and by 
transgenic inhibition of extracellular Wnt signaling through Dkk-1 [62, 63]. In all cases, a 
dramatic reduction of proliferative activity was observed. In the converse experiment, 
activating the Wnt pathway through transgenic expression of the Wnt agonist R-Spondin-1 
resulted in a massive hyperproliferation of intestinal crypts [64]. 
Although Wnt signaling is essential to the normal physiology of the intestine, it was 
first characterized by its association with colorectal cancer, one of the most common cancers 
in industrialized countries. Fearon and Vogelstein [65] have proposed that colorectal cancer 
results from an ordered sequence of mutations in what is called the suppressor pathway. 
Invariably, the initiating mutation occurs in a gene (APC, CTNNB1/-catenin, or AXIN2) that 
encodes for a protein involved in the Wnt/-catenin pathway. Loss of the tumor suppressor 
APC is the signature of the great majority of human intestinal tumors, both in the hereditary 
familial adenomatous polyposis and in sporadic colorectal cancers [66-68]. In the rare cases 
where APC is not inactivated, human colon tumors arise from activating mutations in 
CTNNB1/-catenin itself [69, 70], or from loss-of-function mutations in AXIN2 [71]. As a 
common result, -catenin accumulates in the nucleus, constitutively binds to TCF/LEF 
transcription factors and induces the expression of targets genes mainly involved in cell 
proliferation, leading to the formation of benign yet long-lived adenomas. Subsequently, 
other mutations follow (e.g. in K-RAS, SMAD4, or TP53…), ultimately resulting in 
metastasizing carcinomas. 
 
B. 1,25(OH)2D3 Inhibits the Transcriptional Activity of β-Catenin/TCF Complexes 
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Results from our group have demonstrated that 1,25(OH)2D3 and several analogues 
antagonize the Wnt/-catenin signaling pathway in human colorectal cancer cells. 
1,25(OH)2D3 inhibits the transcriptional activity of -catenin by two mechanisms. First, it 
rapidly increases the amount of VDR bound to -catenin, thus reducing the interaction 
between -catenin and TCF4 [72] (Figure 3A). In this way, 1,25(OH)2D3 modulates 
TCF/LEF target genes in the opposite way to -catenin: those induced by -catenin/TCF4 
such as c-MYC, TCF1, PPAR- or CD44 are repressed by 1,25(OH)2D3, while zonula 
occludens (ZO)-1, which is inhibited by -catenin/TCF4 becomes activated by 1,25(OH)2D3 
[72]. Second, 1,25(OH)2D3 induces β-catenin nuclear export and relocation to the plasma 
membrane adherens junctions. As β-catenin is no longer in the nucleus, transcription of 
TCF/LEF target genes is halted (Figure 3B). This happens concomitantly to an increase in E-
cadherin protein expression. 1,25(OH)2D3 induction of E-cadherin in SW480-ADH human 
colon cancer cells was observed soon after treatment and peaked at 48-72 h, and correlated 
with a change to a more differentiated phenotype [72]. Thus, 1,25(OH)2D3 may cause a 
reduction in nuclear β-catenin concentration by promoting its sequestration at the adherens 
junctions bound to the newly synthesized E-cadherin (Figure 3B). Alternatively, 
1,25(OH)2D3 might stimulate β-catenin nuclear export through yet unknown mechanisms. 
Although APC has been proposed as a contributor to -catenin nuclear export [73], the 
relocation of -catenin takes place in SW480-ADH cells that express a truncated APC 
protein. 
We have shown that transient activation of the RhoA small GTPase is necessary for 
the induction by 1,25(OH)2D3 of the expression of CDH1/E-cadherin and many other genes 
in several cell types [74]. Interestingly, RhoA activity is also required for the promotion of -
catenin nuclear export and for the inhibition of -catenin/TCF4 transcriptional activity and 
cell proliferation [74], suggesting a relationship between E-cadherin expression and nuclear 
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export. Moreover, it is worth noticing that although the export of β-catenin out of the nucleus 
contributes to the inhibition of β-catenin/TCF4-mediated transcriptional activity in some cell 
lines, the global antagonism of 1,25(OH)2D3 on this signaling pathway must be independent 
of E-cadherin induction, as it takes places in LS-174T colon cancer cells that lack E-cadherin 
expression [72]. 
In addition to 1,25(OH)2D3, the vitamin D analogues EB1089, MC903 and KH1060 
[72] and the superagonistic fluorinated CD578, WU515 and WY113 compounds [75] also 
inhibit -catenin/TCF transcriptional activity in a strictly VDR-dependent fashion, as 
inhibition does not occur in SW480-R or SW620 cells that lack VDR expression. Moreover, 
the transcription factors SNAIL1 and SNAIL2 (also called SLUG), which repress VDR 
expression [76, 77], abolish this effect in vitro and in vivo [77, 78]. 
These results indicate that 1,25(OH)2D3 downregulates the Wnt/β-catenin signaling 
pathway, and may thus control the phenotype of colon epithelial cells. Upon -catenin 
stabilization in colon cancer cells due to its own mutation or that of APC or AXIN2, binding 
to VDR may buffer its stimulatory action on TCF4 target genes, a protective effect which can 
be lost along with VDR expression during malignant progression linked to SNAIL1/SNAIL2 
upregulation. Additionally, we found that nuclear β-catenin transiently potentiates VDR 
transcriptional activity before -catenin moves out of the nucleus and/or VDR is 
extinguished [72]. 
Shah and cols. [79] confirmed and extended the finding of VDR/β-catenin interaction. 
These authors have characterized the interacting domains in VDR and -catenin: the 
activator function-2 (AF-2) domain of VDR and the C-terminal region of β-catenin. 
Moreover, they showed that acetylation of β-catenin C-terminal region differentially 
regulates its ability to activate TCF/LEF or VDR-regulated promoters. The mutation of a 
specific residue in the AF-2 domain, which renders a VDR that can bind hormone but is 
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transcriptionally inactive in the context of classical coactivators, still allows interaction with 
β-catenin and ligand-dependent activation of VDRE-containing promoters. Interestingly, 
VDR antagonists, which block the recruitment by VDR of classical coactivators, do allow 
VDR to interact with β-catenin, suggesting that some ligands would permit those functions of 
VDR that involve β-catenin interaction [79]. In addition to human colon cancer cells, the 
inhibition of -catenin/TCF transcriptional activity by 1,25(OH)2D3 or its analogues QW and 
BTW has been found in rat Rama 37 mammary cells [80]. In these cells different -catenin 
transcriptional complexes distinctly modulate the activation of the OPN/Osteopontin gene 
promoter by ligand-activated VDR: β-catenin/LEF1 enhances the activation while -
catenin/TCF4 diminishes it. Recently, Egan and cols. [81] have reported that the inhibition of 
the transcriptional activity of -catenin/TCF complexes by 1,25(OH)2D3 in colon cancer cells 
is enhanced by wild-type APC. In addition, these authors have shown that the VDR ligand 
lithocolic acid also inhibits -catenin transcriptional activity but to a lesser extent than 
1,25(OH)2D3 and concordantly it is also less effective than 1,25(OH)2D3 in promoting VDR 
binding to -catenin. 
Nuclear hormone receptors other than VDR have also been reported to regulate -
catenin transcriptional activity in several types of cells and tissues, reflecting a complex 
crosstalk between hormonal systems and Wnt signaling [82, 83]. 
Notably, a novel mechanism of Wnt/-catenin signaling pathway inhibition by 
1,25(OH)2D3 has recently been reported by Kaler and cols. [84]. These authors have shown 
that THP-1 macrophages activate the Wnt/-catenin signaling pathway in HCT116 and Hke-
3 colon carcinoma cells via the STAT-1-mediated production and secretion of interleukin 
(IL)-1, which blocks GSK3 activity and hence increases -catenin/TCF transcriptional 
activity and proliferation of carcinoma cells (Figure 3D). This mechanism, which might 
contribute to the tumorigenic effect of tumor-associated macrophages in vivo, is repressed by 
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1,25(OH)2D3 through the inhibition of the constitutive activation of STAT-1 and the 
production of IL-1 in macrophages [84] (Figure 3D). 
 
C. 1,25(OH)2D3 Regulates the Wnt Inhibitor DICKKOPF-1 
We have reported that 1,25(OH)2D3 increases
 
the level of DKK-1 RNA and protein in 
SW480-ADH human colon cancer cells and this effect depends
 
on the presence of a 
transcription-competent VDR [85]. The slow kinetics of DKK-1
 
RNA accumulation and the 
lack of VDR binding to the promoter
 
region that is activated by the hormone, together with 
the absence
 
of effect on the half-life of DKK-1 RNA and the requirement
 
of VDR 
transcriptional activity strongly suggest that 1,25(OH)2D3
 
upregulates the transcription of 
DKK-1 via intermediate proteins
 
encoded by early 1,25(OH)2D3 target genes that remain 
uncharacterized. In addition, DKK-1 is upregulated by ectopic E-cadherin
 
in SW480-ADH 
cells, and a blocking antibody against E-cadherin
 
inhibits 1,25(OH)2D3-mediated DKK-1 
induction. These data indicate that the regulatory effect of 1,25(OH)2D3 is an indirect 
consequence
 
of the induction of E-cadherin and the epithelial adhesive phenotype [85]. The 
induction of DKK-1 by 1,25(OH)2D3 constitutes
 
yet another mechanism by which this 
hormone antagonizes the Wnt/β-catenin pathway (Figure 3C). The existence of several 
mechanisms of Wnt/β-catenin signaling antagonism by 1,25(OH)2D3 reinforces its 
importance for the biology and the maintenance of the normal status of the colonic 
epithelium. 
Since most colorectal cancer cells have mutations in APC that render an active Wnt/β-
catenin pathway, the relevance of DKK-1 induction by 1,25(OH)2D3 is uncertain. 
Interestingly, DKK-1 seems to have antitumoral effects independently
 
of the antagonism of 
β-catenin/TCF transcriptional activity in H28 and MS-1 mesothelioma, HeLa cervical, and 
JAR and JEG3 human placental choriocarcinoma cancer
 
cells [86-88]. In line with this, we 
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have shown that in DLD-1 colon cancer cells, which bear
 
a truncated APC gene and so have 
a constitutively
 active Wnt/β-catenin pathway, transfection of DKK-1 decreases cell growth in 
vitro and tumor formation
 
in immunodeficient mice [89]. Activation of the Jun N-terminal 
kinase (JNK) pathway is involved in some of these tumor suppressor effects [86, 88]. Thus, 
DKK-1 may control signaling cascades independently of LRP5/6 and -catenin [41, 90]. 
Additionally, LRP5/6 may have -catenin-independent effects under the control of DKK-1 
[91]. These data indicate that DKK-1
 
can inhibit tumorigenesis by different mechanisms and 
that its induction might be of unforeseen importance for the anticancer action of 
1,25(OH)2D3. 
PLEASE, INSERT FIGURE 3 HERE
 
We and others have observed that, in addition to 1,25(OH)2D3, the transcription of the 
DKK-1
 gene is enhanced by β-catenin/TCF itself acting on several sites in the promoter 
region [92-94]. Our group
 
also reported the downregulation of DKK-1 in human colon cancer 
[93] indicating the loss of this negative feedback control of the Wnt/β-catenin pathway in this 
neoplasia. Reduced DKK-1 expression is due, at least in part, to promoter methylation,
 
which 
is specifically found in 25% of advanced, less differentiated
 
tumors (Dukes’ stages C and D) 
[89]. Thus, the induction of DKK-1 expression by 1,25(OH)2D3 may restore DKK-1 
antitumoral effects in those colon tumors in which DKK-1 downregulation is not due to 
promoter methylation. The finding that DKK-1 expression is silenced in dedifferentiated 
colorectal tumors and the association of DKK-1 expression with the differentiated phenotype 
suggests that DKK-1 accumulation is not only concomitant with, but also plays an active role 
in the differentiation process. Accordingly, we have also demonstrated a significant 
correlation between the expression of VDR and DKK-1 in human colon cancer [85]. VDR is 
considered a marker of differentiation in this neoplasia [95, 96] and its expression is lost 
during colon cancer
 
progression together with that of E-cadherin, and presumably in parallel 
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to
 
the upregulation of the transcription factors SNAIL1 and SNAIL2 that repress both genes 
[76, 77, 97]. 
 
D. 1,25(OH)2D3 Represses DICKKOPF-4 and Induces TCF4 in Colon Cancer Cells 
DKK-4 protein has been described as an antagonist of Wnt/β-catenin signaling [47, 52] and, 
like DKK-1, it has also been shown to be transcriptionally induced by this pathway [98, 99]. 
DKK-4 is a weaker Wnt inhibitor than DKK-1, although its effect is increased if Kremen 2 is 
overexpressed ([52] and our unpublished data). In apparent contradiction, DKK-4 inhibits the 
Wnt/β-catenin pathway but is overexpressed in several pathological diseases including some 
types of cancer, inflammation and schizophrenia [99-103]. We and others have found DKK-4 
RNA expression in human colorectal tumors but not in adjacent normal tissue [99, 102, 104]. 
Moreover, DKK-4 RNA levels are already increased in patients with inflammatory bowel 
disease [105, 106]. These results contrast with the common silencing of the DKK-4 gene in 
colon cancer cell lines that we and others [107] have found and that may be related to cell 
culture conditions. They also contrast with results from Baehs and cols. [108] who have 
reported DKK-4 downregulation in colorectal cancer. 
Notably, 1,25(OH)2D3 inhibits DKK-4 expression in human colorectal (SW480-ADH, 
Caco-2) and breast (MCF-7, MDA-MB-468, MDA-MB-453) cancer cell lines [81, 99]. The 
mechanism of DKK-4 repression is unclear. While in SW480-ADH cells a direct 
transcriptional repression mediated by VDR binding to the promoter is found [99], in Caco-2 
cells a mutant VDR deficient in DNA binding mediates similar repression of DKK-4 to wild-
type VDR [81]. In SW480-ADH cells, 1,25(OH)2D3 promotes the binding of VDR and also 
of the silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor 
to a consensus sequence adjacent to the transcription initiation site and the abrogation of 
histone H4 acetylation. Interestingly, our group showed an inverse correlation between VDR 
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and DKK-4 RNA levels in human colorectal tumors which suggests that the regulation of 
DKK-4 observed in cell lines also occurs in patients [99]. 
In order to characterize DKK-4 effects in colon cancer and thus the importance of its 
regulation by 1,25(OH)2D3, we ectopically expressed DKK-4 in two human colon cancer cell 
lines: SW480-ADH, which expresses low levels of the endogenous gene, and DLD-1, in 
which its expression is not detected. Exogenous DKK-4 protein enhanced the migratory and 
invasive potential in vitro of both cell lines. Moreover, the migration and morphogenetic 
capacity of primary human microvascular endothelial cells (HMVEC) were robustly 
increased in the presence of conditioned medium from DKK-4-expressing cells or 
recombinant DKK-4 protein [99]. Thus, DKK-4 enhances the capacity of colon cancer cells 
to invade and to induce sustained angiogenesis, both essential for incipient neoplasias to 
grow and metastasise. These findings suggest that DKK-4 inhibition by 1,25(OH)2D3 could 
explain some of the antitumoral effects of the hormone in colon cancer. 
Although DKK-4 can act as a Wnt inhibitor, these data support new roles for this 
protein in human colon cancer, probably inducing -catenin-independent actions during the 
progression of this neoplasia. In addition, they suggest that the tumorigenic actions of DKK-
4 could overcome its weak inhibitory effect on the Wnt/-catenin pathway [99]. The effects 
may be dose related: small amounts of DKK-4 may predominantly be inhibitory for Wnt 
signaling while higher levels may promote cell malignancy. Accordingly, Wnt antagonists 
other than DKK-4 are also upregulated and may contribute to tumorigenesis in different 
systems [109-111]. Thus, upregulation of DKK-4 and other Wnt inhibitors in some cancer 
cell types implicate them in roles other than the control of this signaling pathway. 
Byers and cols. [112] have recently reported a decreased expression of Tcf4 (product 
of the TCF7L2 gene in humans) in the mammary gland of Vdr null mice. In addition, these 
authors found that 1,25(OH)2D3 increases TCF4 RNA and protein levels in several human 
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colon cancer cell lines by an indirect mechanism that requires de novo protein synthesis and 
is completely dependent on VDR. This induction is unique to TCF4, as other TCF/LEF 
family members are not upregulated. Although it is generally assumed that binding of β-
catenin to members of the TCF/LEF family is cancer-promoting, recent studies have 
indicated that TCF4 functions instead as a transcriptional repressor with growth inhibitory 
activity. Thus, RNAi-mediated disruption of TCF4 expression facilitates β-catenin activity 
and cell growth in both DLD-1 cells (APC mutation) and HCT116 cells (activating 
CTNNB1/β-catenin mutation) [113]. Also, recent data show that TCF4 expression is lost in 
human breast cancers but abundant in the surrounding normal tissue, indicating that TCF4 
might be a tumor suppressor in this tissue [114]. Consequently, it is possible that the 
1,25(OH)2D3/VDR-mediated increase in TCF4 may have a protective role in colon and breast 
cancer. 
 
IV. WNT AND 1,25(OH)2D3 IN THE BONE 
A. Wnt Signaling and Bone Homeostasis 
The observation that Wnt signaling is critical in bone biology has been a major development 
in the area over the past few years. Bone marrow-derived mesenchymal stem cells (BMSCs) 
can potentially differentiate into adipocytes, chondrocytes, or osteoblasts. Although the 
precise orchestration of Wnt signaling during bone development is dependent on complex 
microenvironmental cues, data from several groups suggest that Wnt signaling is central to 
osteoblastogenesis while it represses differentiation of BMSCs to alternative cell types, such 
as adipocytes [115, 116]. A number of different Wnt proteins play a role in bone formation. 
Wnt10b
-/-
 mice have decreased trabecular bone and serum osteocalcin [117], while transgenic 
mice that express Wnt10b in bone marrow show increased bone mass and strength [117]. The 
expression of Wnt10b in mesenchymal progenitors induced the expression of Runx2 and 
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Osterix, two transcription factors associated with osteoblast differentiation, and stimulated 
osteoblastogenesis [117]. Likewise, Wnt3a
+/-
 and Wnt5a
+/-
 mice showed a decrease in bone 
mass [118] which associates with a reduced number of osteoblasts. Wnt5a does not activate 
Wnt/β-catenin signaling but a non-canonical pathway, and has been shown to induce 
osteoblastogenesis by inactivation of peroxisome proliferator-activated receptor-γ (PPARγ), 
a key adipogenic transcription factor, and activation of Runx2 [118]. Thus both canonical 
and non-canonical Wnt signaling pathways play a role in osteoblast differentiation and bone 
formation. 
The involvement of Wnt/β-catenin signaling in the control of bone biology is further 
supported by findings related to the LRP5 gene. Loss-of-function mutations in this gene were 
associated with low bone mass in the osteoporosis pseudoglioma syndrome (OPPG, [119]), 
whereas a single amino-acid substitution (G171V) in the same gene was associated with a 
high bone mass state in two kindreds [120, 121]. This mutation inhibits the ability of DKK-1 
and potentially other proteins to bind to LRP5 and inhibit Wnt signaling. In line with this, 
mice with disruption of Lrp5 in all cells, similar to patients with OPPG, have a low bone 
mass phenotype which is secondary to reduced osteoblast proliferation [122]. 
Recently, Yadav and cols. [123] have demonstrated that Lrp5 has an important role 
inhibiting serotonin biosynthesis in the gut. Serotonin had previously been implicated in the 
regulation of bone mass [124] and gut-specific deletion of Lrp5 was shown to result in a low 
bone mass phenotype [123]. In contrast, osteoblast-specific deletion of Lrp5 did not cause a 
similar defect. Thus, bone formation appears to be controlled by Lrp5-mediated serotonin 
inhibition in the intestine. It is possible that LRP6, rather than LRP5, is the critical coreceptor 
for Wnt signaling in bone. Consistent with this, the Lrp6 loss of function bone phenotype is 
much more severe than the Lrp5 loss of function phenotype. Although Lrp6
-/-
 mice die at 
birth [125], Lrp6 heterozygous mice display reduced bone mass [126]. In this regard, a 
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missense mutation in LRP6 that resulted in impaired Wnt signaling was reported in a family 
with autosomal dominant early coronary artery disease, metabolic risk factors, and 
osteoporosis [127]. 
Wnt extracellular inhibitors also have a relevant role in bone biology. Dkk-1 
overexpression in transgenic mice resulted in severe osteopenia with a 49% reduction in the 
number of osteoblasts [128]. In contrast, mice engineered to lack Dkk-1 showed increased 
bone formation and bone mass [129]. In humans, elevated expression of DKK-1 in myeloma 
patients has been associated with bone disease [130]. 
SFRP1 has also been identified as a regulator of osteoblast and osteocyte survival, 
with effects on trabecular bone mass. Expression of SFRP1 increases with advancing 
osteoblast differentiation and peak expression of SFRP1 occurs at the pre-osteocyte stage 
[131]. Mechanistically, deletion of Sfrp1 in mice led to a decrease in osteoblast and osteocyte 
apoptosis with a resultant increase in osteocyte number in vivo [132]. 
The Wnt inhibitor Sclerostin, product of the SOST (SclerOSTeosis) gene, also has a 
critical role in the control of bone mass. Sclerostin is produced exclusively by osteocytes and 
inhibits bone formation. Inactivating mutations in SOST result in sclerosteosis, a sclerosing 
bone dysplasia [133, 134]. Targeted deletion of the Sost gene in mice results in increased 
bone formation and strength [135]; conversely transgenic mice overexpressing Sost have low 
bone mass [136]. 
In summary, activation of the Wnt/β-catenin pathway leads to increased bone mass 
while suppression results in bone loss. 
 
B. 1,25(OH)2D3 Promotes Wnt/β-Catenin Signaling in Osteoblasts 
The important role of 1,25(OH)2D3 in bone homeostasis is well known (See chapters 
“Development of the Skeleton”, “Osteoblasts” and “Osteoclasts”). The function of VDR in 
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osteoblasts seems to be modulated as a function of the differentiation stage of the cells. 
Indeed, calvarial osteoblasts from Vdr null mice displayed enhanced osteogenesis in vitro, 
suggesting that VDR activation in pre-osteoblasts suppresses bone formation [137], whereas 
the expression of a Vdr transgene in mature osteoblasts results in increased bone mass [138]. 
This differentiation-dependent effect may however be species-specific, as it is not observed 
in humans (Hans van Leeuwen, personal communication).  
Some of the effects of 1,25(OH)2D3 in the bone are reminiscent of those orchestrated 
by Wnt signaling suggesting a crosstalk between both pathways. Indeed, it has been shown 
that 1,25(OH)2D3 can induce binding of the VDR to a response element within the mouse 
Lrp5 gene in both primary osteoblasts and osteoblastic cell lines [139]. This interaction 
between 1,25(OH)2D3-activated VDR and the Lrp5 gene led to both a modification in 
chromatin structure within the mouse Lrp5 locus and the induction of Lrp5 mRNA 
transcripts in vivo as well as in vitro [139]. Thus, through the induction of Lrp5 expression, 
1,25(OH)2D3 enhances Wnt signaling in mouse osteoblasts. Interestingly, whereas the 
regulatory region in the mouse Lrp5 gene is highly conserved in the human genome, the 
vitamin D response element is not [139], which argues against a conserved mechanism for 
1,25(OH)2D3/Wnt signaling interaction in the bone. 
Studies using BMSCs derived from Vdr-null mice showed that ablation of Vdr did not 
alter osteoblastic differentiation [140]. However, when cultured under adipogenic conditions, 
these BMSCs expressed higher mRNA levels of PPARγ and other markers of adipogenic 
differentiation, and also of mRNA encoding the Wnt inhibitors Dkk-1 and Sfrp2 [140]. This 
increase was, at least in part, due to ligand-dependent actions of the VDR, since 1,25(OH)2D3 
suppressed Dkk-1 and Sfrp2 expression in wild-type cultures. Thus, it is concluded that 
ligand-dependent actions of the VDR in mouse BMSCs promote canonical Wnt signaling by 
inhibiting the expression of Dkk-1 and Sfrp2 and inducing the expression of Lrp5, leading to 
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a repression of adipogenic differentiation (Figure 4). 1,25(OH)2D3 effects on Wnt signaling 
are, however, complex and cell- or tissue-dependent. 1,25(OH)2D3 enhances the induction of 
the negative regulator of bone formation and Wnt inhibitor SOST gene by bone 
morphogenetic protein in human osteoblasts [141] while it represses the SOST homologue 
WISE/SOSTDC1 gene in keratinocytes [142]. Similarly, Dkk-1 expression is inhibited by 
1,25(OH)2D3 in BMSCs while it is induced by the hormone in colon cancer cells [85, 140] 
(Figure 4). 
 
V. WNT AND 1,25(OH)2D3 IN THE SKIN 
A. Wnt Signaling in the Epidermis 
The Wnt/β-catenin signaling pathway controls stem cell differentiation in the skin [143, 144]. 
β-Catenin transcriptional activity promotes differentiation of the hair follicle lineages in 
embryonic and adult epidermis and, in certain circumstances, can expand the stem cell 
compartment [145, 146]. In contrast, β-catenin inhibits sebaceous gland differentiation [143, 
147] and actively suppresses interfollicular epidermis differentiation in developing skin [145, 
146]. Sonic hedgehog and Jagged-1, ligands of the Hedgehog and Notch signaling pathways, 
respectively, are β-catenin target genes in the epidermis and both pathways act downstream 
of β-catenin to induce stem cell expansion and follicle formation [148, 149]. 
Consistent with the relation between aberrant Wnt signaling and cancer, deletion of β-
catenin renders the epidermis resistant to chemically-induced tumors [150]. Moreover, 
prolonged activation of β-catenin in transgenic mice is sufficient to induce benign hair 
follicular tumors (pilomatricomas and trichofolliculomas) [151], which regress when the 
pathway is no longer active [147]. Interestingly, human pilomatricomas have been found to 
harbor activating β-catenin mutations [152]. 
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B. The Vitamin D Receptor Mediates Wnt/β-Catenin Signaling in the Epidermis 
VDR is essential for adult epidermal homeostasis [153] and mutations in the VDR gene in 
humans result in familial 1,25(OH)2D3-resistant rickets, which can be associated with 
alopecia [154]. In vivo, the expression of a mutant Vdr that can bind β-catenin but not 
1,25(OH)2D3 rescues alopecia in Vdr null mice, demonstrating ligand-independent functions 
of VDR in the skin [155]. Vdr null mice fail to undergo the first postnatal hair cycle; instead, 
the hair follicles are converted to cysts of interfollicular epidermis. Two independent groups 
have shown that the absence of Vdr impairs Wnt/-catenin signaling in keratinocytes and 
leads to alopecia [156, 157]. Cianferotti and cols. reported that Vdr ablation results in gradual 
depletion of the hair follicle stem cell pool which correlated with a failure of β-catenin to 
induce proliferation [156]. In contrast, Pálmer and cols. [158] defend that the degeneration of 
Vdr null follicles does not reflect a loss of follicle stem cells. Alternatively, they suggest that 
the failure to maintain the hair follicle may represent an inability of the stem cells to migrate 
along the follicle [158]. These authors also found that many genes that are upregulated by 
active β-catenin contain vitamin D response elements and that several of them are induced 
independently of TCF/LEF. They conclude that unliganded VDR is a Wnt effector and that 
β-catenin acts as VDR coactivator in epidermal keratinocytes [157]. For these researchers, 
the primary role of the VDR/β-catenin interaction in the skin is to promote the transcription 
of genes associated with differentiation of the hair follicle lineages. Although these genes are 
activated by Wnt signals in the absence of 1,25(OH)2D3, the combined treatment has a 
synergic effect [157] (Figure 4). 
Prolonged activation of β-catenin in the absence of VDR results in the development 
not of benign trichofolliculomas but of undifferentiated tumors resembling basal cell 
carcinomas [157]. Conversely, activation of β-catenin in the presence of VDR and the 
vitamin D analog EB1089 prevents β-catenin-induced formation of trichofolliculomas. 
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Interestingly, human trichofolliculomas have cells with high levels of nuclear β-catenin and 
VDR, whereas infiltrative human basal cell carcinomas have high β-catenin levels and low 
VDR levels [157]. Thus, vitamin D analogues may be beneficial in the treatment of skin 
tumors in which the canonical Wnt pathway is activated inappropriately. A corollary to these 
results is that β-catenin can no longer be considered as chiefly an activator of TCF/LEF 
target genes. The interaction of β-catenin with VDR and possibly other transcription factors 
is likely to contribute to the pleiotropic effects of the Wnt pathway, which has different target 
genes in different cell types (Figure 4). 
PLEASE, INSERT FIGURE 4 HERE 
 
VI. CONCLUSIONS 
1,25(OH)2D3 and VDR regulate the Wnt/-catenin signaling pathway depending on the cell 
or tissue type: while 1,25(OH)2D3 and analogues inhibit -catenin transcriptional activity and 
target genes in colon tumor cells, upregulation of the pathway by either ligand-activated or 
unliganded VDR occurs in osteoblasts and keratinocytes. The mechanisms of Wnt signaling 
control by 1,25(OH)2D3 and VDR are diverse: direct VDR/-catenin interaction, induction of 
-catenin nuclear export, variable regulation of the expression of Wnt inhibitors such as 
DKK-1 and -4, WISE/SOSTDC1, SOST and Sfrp2, of the Wnt coreceptor Lrp5 (in mouse 
cells) or of the nuclear -catenin partner TCF4, and repression of IL-1 production by 
stromal macrophages (Figure 4). 
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Figure Legends 
 
Figure 1. Wnt/-catenin signaling pathway. (A) In the absence of Wnt factors, -catenin (-
Cat) is located at plasma membrane adherens junctions bound to E-cadherin. Free -catenin 
is phosphorylated by GSK3 and CK1 in a destruction complex that includes also APC and 
Axin. This phosphorylation targets -catenin for degradation by the proteasome. The 
transcription of Wnt/-catenin target genes is inhibited by TCF/LEF via the recruitment of 
corepressors such as Groucho(Gro)/TLE1. (B) Wnt factors promote the stabilization of 
cytosolic -catenin through the inactivation of the destruction complex. -Catenin enters the 
cell nucleus and associates with TCF/LEF proteins activating the transcription of Wnt/-
catenin target genes. Activated Wnt pathway reduces E-cadherin expression through the 
induction of transcriptional repressors of CDH1/E-cadherin gene and of proteases that 
degrade E-cadherin protein (for a review see [159]).   
 
Figure 2. Extracellular inhibitors of Wnt signaling. WIF-1, SFRPs and Cerberus bind 
directly to Wnt factors and block their interaction with Frizzled receptors. DKK and 
WISE/SOST families bind to LRP coreceptors and prevent Wnt-Frizzled-LRP interaction 
and signaling. In addition, DKKs induce LRP endocytosis in the presence of Kremen 
proteins. 
 
Figure 3. 1,25(OH)2D3 inhibits Wnt/-catenin signaling in colon cancer cells by several 
mechanisms. (A) Ligand-activated VDR binds to -catenin and inhibits the formation of 
transcriptionally competent -catenin/TCF4 complexes. (B) 1,25(OH)2D3 induces E-cadherin 
expression and promotes -catenin nuclear export and relocation at plasma membrane 
adherens junctions bound to newly synthesised E-cadherin. (C) 1,25(OH)2D3 induces the 
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expression of the DKK-1 Wnt inhibitor. (D) 1,25(OH)2D3 inhibits IL-1 secretion by tumor-
associated macrophages and thus blocks the IL-1-dependent inhibition of GSK3 activity 
and subsequent -catenin stabilization in cancer cells. 
 
Figure 4. The interplay between Wnt/-catenin pathway and 1,25(OH)2D3/VDR depends on 
the cell or tissue type. In colon cancer cells, 1,25(OH)2D3/VDR inhibits -catenin 
transcriptional activity and target genes through the inhibition of -catenin/TCF interaction, 
the induction of -catenin nuclear export, and the regulation of DKK-1, DKK-4, TCF4 and 
IL-1. In mouse osteoblasts and bone marrow stem cells, 1,25(OH)2D3/VDR upregulates 
Wnt/-catenin signaling through the induction of Lrp5 and the repression of Dkk-1 and 
Sfrp2. In human osteoblasts, 1,25(OH)2D3 potentiates SOST induction by bone 
morphogenetic proteins. Unliganded VDR mediates the activation of Wnt/-catenin target 
genes in mouse keratinocytes promoting hair follicle differentiation and inhibiting the 
formation of infiltrative basal cell carcinomas. In human keratinocytes, 1,25(OH)2D3 
represses WISE/SOSTDC1. 
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